A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16
11. Dezember 2014 aktualisiert von: Janssen Research & Development, LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16
The main purposes of this study are to evaluate the safety (Parts 1 and 2) and efficacy (Part 2) of pretreatment with CNTO 3157 in healthy adult and asthmatic adult participants before and after intranasal (into the nose) inoculation with human rhinovirus type 16 (HRV-16).
Studienübersicht
Status
Abgeschlossen
Bedingungen
Detaillierte Beschreibung
This is a two-part, randomized (participants are assigned to treatment by chance), double-blind (participants and investigators do not know what study agent is being administered), placebo-controlled study.
A placebo appears identical to a study agent, has no active ingredients, and helps investigators evaluate the effect of a study agent.
In Part 1, following administration of CNTO 3157 or placebo, the severity of an upper respiratory tract infection, due to inoculation with HRV 16, will be assessed in healthy participants for safety reasons.
In Part 2, following administration of CNTO 3157 or placebo and inoculation with HRV-16, efficacy and safety will be assessed in asthmatic participants using standard assessments to evaluate asthma treatments.
The study (Parts 1 and 2) will be completed when the last participant completes the last visit (Week 11) in Part 2.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
76
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Antwerp, Belgien
-
-
-
-
-
Borstel, Deutschland
-
Frankfurt, Deutschland
-
-
-
-
-
Hellerup, Dänemark
-
Kobenhavn Nv, Dänemark
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada
-
-
-
-
-
Amsterdam Zuidoost, Niederlande
-
Groningen, Niederlande
-
-
-
-
-
Belfast, Vereinigtes Königreich
-
Dundee, Vereinigtes Königreich
-
London, Vereinigtes Königreich
-
Manchester, Vereinigtes Königreich
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Understanding of the study and a signed informed consent form before any study-related procedures
- Willing and able to adhere to the restrictions specified in the protocol
- Results of the following laboratory tests within the following limits: serum alanine aminotransferase (ALT) levels ≤2 x ULN; serum aspartate aminotransferase (AST) levels ≤2 x ULN
- Part 1 (healthy participants):
- a). Body weight in the range of 40 to 125 kg, inclusive. Have a body mass index (BMI) of 19 to 32 kg/m2, inclusive
- b). Healthy with no clinically significant abnormalities as determined by medical history, physical examination, blood chemistry assessments, hematologic assessments, coagulation and urinalysis, measurement of vital signs, and 12-lead electrocardiogram (ECG) performed at Screening Visit 2
- Part 2:
- a). (BMI) of 19 to 40 kg/m2, inclusive; have a physician-documented diagnosis of asthma for at least 6 months prior to Screening Visit 2; have stable asthma based on physician assessment at Screening Visit 2
- b). Have an Asthma Control Questionnaire (ACQ) symptom score less than (<)2.5 at Screening Visit 2
- c). Have a prebronchodilator forced expiratory volume in the first second (FEV1) greater than or equal to (>=) 65 percent of predicted normal value at Screening Visit 2
Exclusion Criteria:
- Part 1 (healthy participants): Has any condition that in the opinion of the investigators, would constitute a risk or a contraindication for participating in the study, prevent the participant from meeting or performing study requirements, or could interfere with the study objectives, conduct, or evaluation
- At Screening Visit 1 and throughout the study, works with (or lives with a family member who cares for) the elderly, (eg, nursing home), or lives with someone who may be at risk from transmission of the human rhinovirus type 16 (HRV-16) challenge agent, including, but not limited to, individuals with chronic lung disease (including asthma), a premature infant, or an immunocompromised individual
- Has had any acute illness, including a common cold, within 4 weeks prior to Screening Visit 1, or has had a major illness or hospitalization within 6 months prior to Screening Visit 1
- Has active allergic rhinitis or perennial allergy symptoms (eg, due to ragweed) at Screening Visit 2 or expects to have active allergic rhinitis or perennial allergy symptoms during the study
- Has a current infection (eg, sepsis, pneumonia or pyelonephritis), or has been hospitalized and/or received antimicrobials for a serious infection during the 6 months prior to Screening Visit 1
- Part 2 (asthmatic patients): Has a history of any other chronic lung disease, including chronic obstructive pulmonary disease (COPD), bronchiolitis, bronchiectasis, allergic bronchopulmonary aspergillosis (mycosis), occupational asthma, sleep apnea, pulmonary hypertension, or any other obstructive pulmonary disease, liver or renal insufficiency; significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, or other body system disorders that are clinically significant in the opinion of the investigator
- Has ever had an episode of life-threatening asthma defined as respiratory arrest or requiring intubation for asthma
- Has been hospitalized (for greater than 24 hours) due to asthma in the 5 years prior to Screening Visit 1
- Has experienced an asthma exacerbation in the 12 weeks prior to Screening Visit 1 requiring management with systemic steroids
- Is receiving a high-dose inhaled corticosteroid (ICS) (>500 µg/day to fluticasone or equivalent). Use of low or medium dose ICS (≤500 µg/day fluticasone or equivalent) with or without permitted controller medications, eg, long-acting Beta2 agonists (LABA), leukotriene receptor antagonists (LTRA), is allowed
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Part 1: Healthy participants (CNTO 3157 + HRV-16)
|
CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
|
|
Placebo-Komparator: Part 1: Healthy participants (placebo + HRV-16)
|
Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
|
|
Experimental: Part 2: Asthmatic patients (CNTO 3157 + HRV-16)
|
Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22).
The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
|
|
Placebo-Komparator: Part 2: Asthmatic patients (placebo + HRV-16)
|
Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22).
The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
The maximum percent decrease relative to baseline in the prebronchodilator forced expiratory volume in 1 second (FEV1) measurements (Part 2)
Zeitfenster: Up to 10 days after inoculation with human rhinovirus type 16 (HRV-16)
|
Up to 10 days after inoculation with human rhinovirus type 16 (HRV-16)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Area under the serum concentration versus time curve (AUC) of change from baseline in Cold Symptom Assessment Score
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Cold symptoms is rated using a 5 point scale (0=none and 4=very severe).
Scores can range from 0-32, with higher scores indicating more symptoms.
|
Up to 10 days after inoculation with HRV-16
|
|
AUC of change from baseline in Cold and Chest Symptom Scale
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Cold and chest symptoms are rated using a 5 point scale: 0 using a 5 point scale (0=none and 4=very severe).
Scores can range from 0-60, with higher scores indicating more symptoms.
|
Up to 10 days after inoculation with HRV-16
|
|
AUC of change from baseline in log-transformed fractional concentration of exhaled nitric oxide (FENO)
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
AUC of the percent change from baseline in clinic assessed prebronchodilator FEV1
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
AUC of change from baseline in morning (AM) peak expiratory flow rate (PEFR)
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
AUC of the change from baseline in prebronchodilator percent predicted FEV1
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
AUC of the change from baseline in prebronchodilator forced vital capacity (FVC)
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
AUC of the change from baseline in prebronchodilator forced expiratory flow at 25 to 75% of vital capacity (FEV25-75)
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
AUC of the change from baseline in prebronchodilator FEV1/FVC
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
AUC of change from baseline in average total asthma symptom diary score
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
Change from baseline in Asthma Control Questionnaire (ACQ)
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
ACQ is an instrument designed to evaluate asthma control.
Seven items are scored on a 7-point scale (0=good control, 6=poor control) with the mean score as an overall summary score.
Questions 1-6 are completed by the patient; the last item is entered by site personnel and corresponds to the patient's percent predicted FEV1 categorized according to the 7-point scale.
Higher scores reflect poorer control.
|
Up to 10 days after inoculation with HRV-16
|
|
Change from baseline in Cold Symptom Assessment Score
Zeitfenster: Up to 11 weeks
|
Clinical symptoms to HRV-16 will be assessed by using the Cold Symptom Assessment Score, wherein participants will report the presence and severity of their cold symptoms in the context of the previous 24 hours via an interactive interview with the study staff.
The symptoms consist of nasal congestion (stuffy nose), rhinorrhea (runny nose), sore throat, sneezing, cough, headache, malaise (feeling run down, tired) and chilliness.
Severity is rated using a 5 point scale (0=none, 1=mild, 2=moderate, 3=severe, and 4=very severe).
Scores can range from 0-32, with higher scores indicating more symptoms.
|
Up to 11 weeks
|
|
Change from baseline in Cold and Chest Symptom Scale
Zeitfenster: Up to 11 weeks
|
The Cold and Chest Symptom Scale contains 15 items composing 2 domains, a total cold score and a total chest score. Together, these 2 domains comprise the chest symptom assessment score. Total Cold Score domain: sneezing, runny nose, blocked or stuff nose, sore throat or hoarse voice, headache or face pain, generally unwell, chills, fever or shivery and cough and Total Chest Score domain: cough on waking, wheeze on waking, daytime cough, daytime wheeze, daytime chest tightness, daytime breathlessness and nocturnal cough, wheeze and breathlessness. Severity is rated using a 5 point scale: 0 using a 5 point scale (0=none, 1=mild, 2=moderate, 3=severe, and 4=very severe). Scores can range from 0-60, with higher scores indicating more symptoms. |
Up to 11 weeks
|
|
Change from baseline in log-transformed FENO over time
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline over time in prebronchodilator and postbronchodilator FEV1
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline over time in percent-predicted prebronchodilator and postbronchodilator FEV1
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline over time in prebronchodilator and postbronchodilator FVC
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline over time in prebronchodilator and postbronchodilator FEV25-75
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline over time in prebronchodilator and postbronchodilator FEV1/FVC
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline in morning/evening PEFR over time
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline in Total Nasal and Ocular Symptom Score (TNOSS)
Zeitfenster: Up to Day 22
|
Nose and eye symptoms are rated by the patient using a 5-point categorical response scale from 0 to 4, where 0 indicates absent/no symptom, and 4 indicates extremely severe symptoms, with a 24-hour recall period.
|
Up to Day 22
|
|
Change from baseline in average total asthma symptom diary score
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline in average number of nocturnal awakenings
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Change from baseline in average rescue medication use over time
Zeitfenster: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Number of symptom-free days
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
The maximum decrease from baseline in the prebronchodilator FEV1 measurements
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
|
|
Time to the maximum decrease relative to baseline in prebronchodilator FEV1
Zeitfenster: Up to 10 days after inoculation with HRV-16
|
Up to 10 days after inoculation with HRV-16
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Oktober 2012
Primärer Abschluss (Tatsächlich)
1. November 2014
Studienabschluss (Tatsächlich)
1. November 2014
Studienanmeldedaten
Zuerst eingereicht
8. Oktober 2012
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
10. Oktober 2012
Zuerst gepostet (Schätzen)
11. Oktober 2012
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
12. Dezember 2014
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
11. Dezember 2014
Zuletzt verifiziert
1. Dezember 2014
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CR100889
- CNTO3157ASH1002 (Andere Kennung: Janssen Research & Development, LLC)
- 2011-005369-19 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur CNTO 3157 (healthy participants)
-
Centocor, Inc.AbgeschlossenAsthmaDeutschland, Vereinigtes Königreich, Belgien